Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma

作者：Bethge W A^*; von Harsdorf S; Bornhauser M; Federmann B; Stelljes M; Trenschel R; Baurmann H; Dittmann H; Faul C; Vogel W; Kanz L; Bunjes D

来源：Bone Marrow Transplantation, 2012, 47(11): 1397-1402.

DOI：10.1038/bmt.2012.62

• radioimmunotherapy
• dose escalation
• allogeneic hematopoietic cell transplantation
• reduced intensity conditioning
• non-Hodgkin lymphoma

A total of 20 patients enrolled in a multicenter phase II dose escalation study of radioimmunotherapy (RIT) using yttrium-90-ibritumomab tiuxetan at two dose levels (22 and 30 MBq/kg) in 10 patients, combined with reduced intensity conditioning (RIC) using fludarabine, melphalan and alemtuzumab followed by allogeneic hematopoietic cell transplantation (HCT) from either ;matched-related (n = 5) or matched-unrelated donors (n = 15). Postgrafting immunosuppression with cyclosporine was administered. Diagnoses were diffuse large B-cell lymphoma (n = 13), transformed CLL (n = 4), blastic mantle cell lymphoma (n = 2) and follicular lymphoma grade 3 (n = 1). Median age was 51 (range, 29-69) years. All patients were high risk with relapsed/refractory disease or relapse after preceding autologous HCT. Median follow-up of patients alive was 1115 (range, 1006-1252) days. No directly RIT-related toxicities were observed. The cumulative incidence of non-relapse mortality was 30%. Incidences of grade II-IV acute and chronic GvHD was 45% and 70%, respectively. Kaplan-Meier estimated 3-year OS and EFS were 20% for both dose levels. In conclusion, dose escalation of RIT and combined use with RIC is feasible with no additional toxicity due to dose escalation. This study is registered on http://clinicaltrials.govas NCT00302757. Bone Marrow Transplantation (2012) 47, 1397-1402; doi:10.1038/bmt.2012.62; published online 16 April 2012

• 出版日期2012-11